Exact Sciences Corp. is set to merge with Abbott Laboratories by Q2 2026, a move contingent on regulatory approvals. The company also recently cleared a waiting period for its deal with Freenome Holdings. In 2025, Exact Sciences reported an 18% revenue increase, reaching $3.25 billion, with screening revenue specifically growing by 26% due to Cologuard tests and PreventionGenetics.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Key facts: Exact Sciences to merge with Abbott by Q2 2026; 2025 revenue up 18%
Exact Sciences Corp. is set to merge with Abbott Laboratories by Q2 2026, a move contingent on regulatory approvals. The company also recently cleared a waiting period for its deal with Freenome Holdings. In 2025, Exact Sciences reported an 18% revenue increase, reaching $3.25 billion, with screening revenue specifically growing by 26% due to Cologuard tests and PreventionGenetics.